Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 797 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Celgene Clear all
Terminated Phase 1 Interventional

Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer

NCT02018523
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Lenalidomide
Drug
Lead sponsor
Jun Zhang
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Oct 15, 2026, 4:05 AM EDT
Completed Phase 1 Interventional

A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies

NCT00046423
View directory record Official record
Conditions
Neoplasms, Metastases, Neoplasm
Interventions
ABI-007
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2016 · Synced Oct 15, 2026, 4:05 AM EDT
Completed Phase 1 Interventional

Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine

NCT01519011
View directory record Official record
Conditions
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
Interventions
oral azacitidine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
8
States / cities
La Jolla, California • Denver, Colorado • Las Vegas, Nevada + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 15, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer

NCT00392392
View directory record Official record
Conditions
Breast Cancer
Interventions
nab-paclitaxel, Bevacizumab, Trastuzumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
6
States / cities
Fort Myers, Florida • Orlando, Florida • Gainesville, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 15, 2026, 4:05 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer

NCT00988208
View directory record Official record
Conditions
Prostate Cancer
Interventions
Lenalidomide, Docetaxel, Prednisone, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,059 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
66
States / cities
Phoenix, Arizona • Sedona, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 15, 2026, 4:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab

NCT02330562
View directory record Official record
Conditions
Malignant Glioma, Glioblastoma
Interventions
MRZ, BEV
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
4
States / cities
Orange, California • Santa Monica, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Oct 15, 2026, 4:05 AM EDT
Terminated Phase 2 Interventional Results available

Lenalidomide Maintenance Therapy for Multiple Myeloma

NCT01675141
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Oct 15, 2026, 4:05 AM EDT
Completed Phase 1 Interventional

Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT00736619
View directory record Official record
Conditions
HEAD & NECK Cancer
Interventions
Cetuximab, IMRT, Albumin-bound paclitaxel (Abraxane®)
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Oct 15, 2026, 4:05 AM EDT
Completed Phase 2 Interventional

Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma

NCT00151203
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Clarithromycin, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 15, 2026, 4:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Carfilzomib and Lenalidomide With Dexamethasone Combination in Newly Diagnosed, Previously Untreated Multiple Myeloma

NCT01029054
View directory record Official record
Conditions
Multiple Myeloma
Interventions
carfilzomib, lenalidomide plus dexamethasone
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
4
States / cities
Ann Arbor, Michigan • St Louis, Missouri • Hackensack, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 15, 2026, 4:05 AM EDT
Completed Phase 1 Interventional

Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction

NCT01578954
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Lenalidomide
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Oct 15, 2026, 4:05 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Apremilast in the Treatment of Moderate to Severe Acne

NCT01074502
View directory record Official record
Conditions
Acne
Interventions
apremilast
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 15, 2026, 4:05 AM EDT
Not listed Phase 1Phase 2 Interventional

Ixazomib with Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients with Multiple Myeloma

NCT02542657
View directory record Official record
Conditions
Myeloma
Interventions
Clarithromycin, Dexamethasone, Ixazomib Citrate, Pomalidomide
Drug
Lead sponsor
Joseph Tuscano
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
3
States / cities
La Jolla, California • Orange, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 15, 2026, 4:05 AM EDT
Completed Phase 3 Interventional Results available

A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

NCT02631070
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Luspatercept, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
13
States / cities
Stanford, California • New Haven, Connecticut • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 15, 2026, 4:05 AM EDT
Completed Phase 1 Interventional

A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving

NCT01684150
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders
Interventions
EPZ-5676
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
Scottsdale, Arizona • Chicago, Illinois • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 15, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma

NCT00413036
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin's
Interventions
lenalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
20
States / cities
Muscle Shoals, Alabama • Scottsdale, Arizona • Fountain Valley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 15, 2026, 4:05 AM EDT
Completed Phase 3 Interventional Results available

Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)

NCT01964430
View directory record Official record
Conditions
Pancreatic Neoplasms, Digestive System Neoplasms, Neoplasms by Site, Neoplasms, Endocrine Gland Neoplasms, Pancreatic Diseases, Digestive System Diseases, Endocrine System Diseases, Gemcitabine, Antimetabolites, Antineoplastic
Interventions
nab-Paclitaxel, Gemcitabine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
866 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
107
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 51 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 15, 2026, 4:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma

NCT01755975
View directory record Official record
Conditions
Multiple Myeloma, Non-Hodgkin's Lymphoma
Interventions
Romidepsin, Lenalidomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
7
States / cities
Hartford, Connecticut • Omaha, Nebraska • Basking Ridge, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2024 · Synced Oct 15, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

Cetuximab and Lenalidomide in Head and Neck

NCT01133665
View directory record Official record
Conditions
Squamous Cell Carcinoma
Interventions
Cetuximab and Lenalidomide
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 15, 2026, 4:05 AM EDT
Completed Phase 3 Interventional Results available

Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

NCT03440385
View directory record Official record
Conditions
Crohn Disease
Interventions
Ozanimod, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
81
States / cities
Scottsdale, Arizona • La Jolla, California • Lancaster, California + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 15, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

NCT02317991
View directory record Official record
Conditions
Gastroesophageal Cancer
Interventions
nab-paclitaxel, ramucirumab
Drug · Biological
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
11
States / cities
Denver, Colorado • Fort Myers, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 15, 2026, 4:05 AM EDT
Terminated Phase 2 Interventional Results available

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

NCT02887248
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer, Transitional Cell Carcinoma
Interventions
nab-paclitaxel, Gemcitabine
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Fort Myers, Florida • St. Petersburg, Florida • West Palm Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 15, 2026, 4:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants

NCT05899738
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Iberdomide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 15, 2026, 4:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of the Effect on Cyclosporine on Ozanimod and Major Active Metabolites

NCT04149678
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Ozanimod, Cyclosporine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Oct 15, 2026, 4:05 AM EDT